Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Market Cap
$692.74B
P/E Ratio
79.83
1Y Stock Return
23.14%
1Y Revenue Growth
27.41%
Dividend Yield
0.78%
Price to Book
48.7
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
MarketWatch
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
SeekingAlpha
Despite attractive valuation metrics, Hershey faces challenges like stagnant earnings growth. Read why HSY stock is a compelling value investment.
Yahoo
We recently compiled a list of the Jim Cramer’s Lightning Round: 8 Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Jim Cramer’s other stocks. Jim Cramer, the host of Mad Money, recently shared his insights on several key topics. He discussed the […]
MarketWatch
Eli Lilly & Co. stock outperforms competitors on strong trading day
Yahoo
Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.
Yahoo
Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade. Last year, the company spent about $2 billion to acquire Versanis' drug that acts directly on fat cells, without prompting lean mass loss. Several other drugmakers including Regeneron and Scholar Rock are testing treatments that could help preserve muscle, which is often lost when patients lose weight through lifestyle changes, bariatric surgery or the use of GLP-1 treatments such as Lilly's Zepbound and Novo Nordisk's Wegovy.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NVO | 59.91% | $342.62B | -0.15% | 1.40% |
TT | 40.81% | $92.94B | +82.73% | 0.79% |
NVMI | 37.84% | $5.16B | +44.02% | 0.00% |
COST | 37.61% | $412.13B | +62.81% | 0.49% |
WING | 36.48% | $9.80B | +45.66% | 0.29% |
SNPS | 34.45% | $82.03B | -1.18% | 0.00% |
CDNS | 34.02% | $82.18B | +10.81% | 0.00% |
ETN | 33.54% | $143.73B | +60.21% | 1.02% |
VRT | 33.41% | $52.90B | +230.61% | 0.07% |
ISRG | 32.15% | $191.92B | +72.80% | 0.00% |
NU | 32.01% | $63.92B | +64.95% | 0.00% |
BSX | 32.00% | $133.13B | +63.29% | 0.00% |
SMCI | 31.97% | $16.55B | -2.47% | 0.00% |
HROW | 31.71% | $1.41B | +330.59% | 0.00% |
META | 31.58% | $1.42T | +66.51% | 0.27% |
SAP | 31.45% | $268.13B | +52.92% | 1.02% |
CYBR | 31.13% | $13.73B | +64.93% | 0.00% |
ALDX | 31.07% | $294.18M | +102.46% | 0.00% |
AMAT | 30.91% | $139.58B | +13.44% | 0.85% |
REGN | 30.72% | $81.82B | -6.79% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CAL | <0.01% | $1.05B | -0.50% | 0.95% |
DXPE | <0.01% | $1.07B | +119.39% | 0.00% |
NGS | 0.01% | $320.33M | +71.20% | 0.00% |
QUAD | 0.01% | $366.66M | +43.76% | 2.84% |
SIBN | 0.01% | $516.68M | -29.40% | 0.00% |
SPR | -0.01% | $3.72B | +23.27% | 0.00% |
CPK | 0.02% | $2.98B | +43.15% | 1.89% |
IART | -0.02% | $1.77B | -40.82% | 0.00% |
SSTK | 0.02% | $1.03B | -34.23% | 3.95% |
GEL | 0.02% | $1.44B | +2.81% | 5.24% |
AMWL | -0.03% | $121.95M | -67.11% | 0.00% |
SAGE | -0.03% | $300.36M | -74.61% | 0.00% |
BWIN | 0.03% | $2.99B | +140.33% | 0.00% |
NECB | 0.03% | $415.57M | +76.37% | 1.37% |
STLD | -0.03% | $21.35B | +24.48% | 1.28% |
KBR | 0.04% | $7.77B | +11.73% | 1.00% |
SNCR | 0.04% | $97.34M | +78.17% | 0.00% |
PACB | 0.04% | $471.05M | -79.23% | 0.00% |
HLIO | 0.05% | $1.68B | +26.81% | 0.72% |
LADR | 0.05% | $1.49B | +6.01% | 7.91% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
NFLT | 0.04% | $199.18M | 0.5% |
VRP | -0.05% | $1.83B | 0.5% |
IBDV | 0.07% | $1.39B | 0.1% |
LDSF | 0.10% | $131.03M | 0.75% |
IBDW | 0.10% | $1.18B | 0.1% |
HTAB | 0.13% | $437.10M | 0.4% |
HYMB | 0.14% | $2.81B | 0.35% |
PWZ | -0.16% | $697.36M | 0.28% |
TLH | 0.18% | $7.01B | 0.15% |
PREF | -0.18% | $999.92M | 0.55% |
TOTL | -0.19% | $3.31B | 0.55% |
GTO | -0.19% | $1.77B | 0.25% |
BSCU | 0.20% | $1.03B | 0.1% |
TAN | 0.21% | $864.71M | 0.67% |
SHYD | -0.21% | $311.50M | 0.35% |
CGMU | 0.21% | $2.53B | 0.27% |
FBND | 0.23% | $15.84B | 0.36% |
CORP | 0.29% | $1.25B | 0.23% |
FMHI | -0.30% | $747.15M | 0.7% |
VEGI | 0.30% | $98.20M | 0.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EGHT | -23.94% | $351.48M | -7.88% | 0.00% |
GTN | -22.20% | $433.55M | -45.83% | 7.40% |
SMP | -21.11% | $690.97M | -10.09% | 3.65% |
BLMN | -20.78% | $1.07B | -47.34% | 5.76% |
SPTN | -20.67% | $615.01M | -17.44% | 4.80% |
BMBL | -20.56% | $845.98M | -43.90% | 0.00% |
FDP | -20.17% | $1.62B | +45.67% | 2.97% |
BALY | -19.37% | $726.31M | +54.50% | 0.00% |
FCF | -18.77% | $1.89B | +40.91% | 2.77% |
PCH | -18.73% | $3.28B | -11.32% | 4.36% |
HUSA | -18.70% | $16.69M | -11.56% | 0.00% |
TBI | -18.66% | $199.52M | -50.80% | 0.00% |
CUBI | -18.63% | $1.69B | +20.59% | 0.00% |
RES | -18.43% | $1.26B | -20.54% | 2.74% |
WBD | -18.16% | $23.31B | -10.21% | 0.00% |
UUU | -18.00% | $4.97M | -41.89% | 0.00% |
PLOW | -17.98% | $572.50M | -7.57% | 4.79% |
CMP | -17.93% | $608.06M | -42.29% | 2.05% |
BWA | -17.70% | $7.25B | -2.62% | 1.34% |
SNDR | -17.56% | $5.41B | +35.80% | 1.22% |
Current Value
$735.791 Year Return
Current Value
$735.791 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TPMN | -39.12% | $40.60M | 0.65% |
VIXY | -30.00% | $195.31M | 0.85% |
TAIL | -28.01% | $67.98M | 0.59% |
SOYB | -13.27% | $27.32M | 0.22% |
KRE | -12.38% | $4.68B | 0.35% |
JPST | -11.79% | $28.43B | 0.18% |
XONE | -11.68% | $548.88M | 0.03% |
IBTF | -11.13% | $2.05B | 0.07% |
FTSM | -10.99% | $6.08B | 0.45% |
XHLF | -10.82% | $874.27M | 0.03% |
CGSM | -10.69% | $514.53M | 0.25% |
VUSB | -10.54% | $4.64B | 0.1% |
SPTS | -9.98% | $5.71B | 0.03% |
GSY | -9.96% | $2.29B | 0.23% |
ICSH | -9.93% | $5.57B | 0.08% |
VGSH | -9.82% | $19.14B | 0.04% |
BOXX | -9.82% | $4.43B | 0.1949% |
MUST | -9.78% | $410.00M | 0.23% |
HYD | -9.71% | $3.18B | 0.32% |
AGZ | -9.71% | $708.37M | 0.2% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IHE | 60.90% | $596.23M | 0.39% |
PPH | 60.45% | $592.06M | 0.36% |
IXJ | 51.67% | $3.89B | 0.41% |
IYH | 51.45% | $3.19B | 0.39% |
XLV | 48.79% | $38.41B | 0.09% |
FHLC | 47.26% | $2.73B | 0.084% |
VHT | 46.71% | $17.06B | 0.1% |
SPMO | 45.07% | $3.92B | 0.13% |
MTUM | 44.86% | $13.13B | 0.15% |
WINN | 42.72% | $620.54M | 0.57% |
JGRO | 42.56% | $3.98B | 0.44% |
FFOG | 42.16% | $118.40M | 0.55% |
QUAL | 41.26% | $50.11B | 0.15% |
TCHP | 40.66% | $890.14M | 0.57% |
SPYI | 40.16% | $2.33B | 0.68% |
FBCG | 39.89% | $2.55B | 0.59% |
PLDR | 39.86% | $676.26M | 0.59% |
CGGO | 39.54% | $4.67B | 0.47% |
MGK | 39.47% | $23.81B | 0.07% |
FTQI | 39.39% | $492.22M | 0.75% |